【摘要】 目的:观察沙利度胺联合化疗治疗急性白血病的临床疗效及其对血浆血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)水平的影响。方法:将急性白血病患者36例随机分为实验组及对照组,各18例。两组均予以常规化疗方案标准剂量化疗,实验组同时长期口服沙利度胺100 mg/d。治疗前、治疗后8周分别检测血浆VEGF、bFGF含量,并选择健康体检者15例,检测其血浆VEGF、bFGF含量为标准对照数值,与白血病患者比较。结果:实验组与对照组患者治疗的有效率分别为88.9%(16/18)、77.8%(14/18),两组差异有统计学意义(χ2=4.10,P<0.05)。实验组与对照组治疗前后血浆VEGF、bFGF水平分别为[(389.78±249.94)ng/L、(211.74±36.72)ng/L]、[(318.54±125.78)ng/L、(288.02±31.77)ng/L]、[(2.43±0.27)μg/L、(2.09±0.17)μg/L]、[(2.41±0.33)μg/L、(2.11±0.31)μg/L],与健康组[(132.91±26.66)ng/L、(1.83±0.44)μg/L]相比,差异有统计学意义(P<0.05);实验组与对照组治疗后VEGF水平相比差异有统计学意义(t=2.79,P<0.05),而bFGF水平差异无统计学意义(t=1.28,P>0.05)。结论:沙利度胺联合化疗可提高急性白血病患者的缓解率,其作用机制可能通过抑制血浆VEGF及其受体水平的表达而发挥其抗血管增殖的抗白血病作用。更多还原

【Abstract】 Objective: To observe the clinical effect and the influence of Thalidomide combined with chemotherapy on the level of plasma vascular endothelial growth factor(VEGF) and basic fibroblast growth factor(bFGF) in acute leukemia before and after treatment.Methods: 36 cases of acute leukemia patients were randomly divided into experimental group and control group,each 18 cases.Each group was treated with conventional chemotherapy in the standard-dose,meanwhile the experimental group was given Thalidomide 100 mg/d additionally.Before treatment and 8 weeks after treatment,plasma were collected for the detection of VEGF,bFGF content.Plasma VEGF and bFGF in 15 cases of healthy people were detected as the standard control value,compared with Leukemia patients.Results: The effective rate of experimental group and control group were 88.9%(16/18),77.8%(14/18) respectively,the difference was statistically significant(χ2=4.10,P<0.05).The level of plasma VEGF and bFGF of experimental group and control group before and after treatment were[(389.78±249.94)ng/L,(211.74±36.72)ng/L],[(318.54±125.78)ng/L,(288.02±31.77)ng/L],[(2.43±0.27)μg/L,(2.09±0.17)μg/L],[(2.41±0.33)μg/L,(2.11±0.31)μg/L],the difference were significant compared with healthy group[(132.91±26.66)ng/L,(1.83±0.44)μg/L](P<0.05);the level of plasma VEGF of experimental group after treatment was significantly different compared with control group(t=2.79,P<0.05),but the level of plasma bFGF shows no difference between experimental group and control group(t=1.28,P>0.05).Conclusion: Thalidomide combined with chemotherapy can improve the remission rate in patients with acute leukemia,and its mechanism may be conduced through inhibiting the plasma levels of VEGF and its receptor expression to active anti-proliferative,then take effect on anti-leukemia effection.更多还原